Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma

APPROVED_FOR_MARKETING

Conditions studied: Soft Tissue Sarcoma

In brief

The purpose of this study is to continue to provide olaratumab to eligible patients who are currently receiving olaratumab commercially for the treatment of soft tissue sarcoma (STS).

Key facts

Study ID

NCT03994627

Run by

Eli Lilly and Company

Last updated by the study team

2024-12-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Are currently receiving olaratumab and who, in consultation with their treating physician, want to continue their course of therapy.
• Have metastatic or locally advanced unresectable soft tissue sarcoma not amenable to curative treatment with surgery or radiotherapy.
• Have given written informed consent.
• Have an absolute neutrophil count (ANC) ≥1,000/microliter.
• Females of childbearing potential and males must agree to use highly effective contraceptive precautions during treatment with olaratumab and up to 3 months following the last dose of olaratumab. A highly effective method of birth control is defined as one that results in a low failure rate (that is, <1% per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices (IUDs), sexual abstinence, or a vasectomized partner.

You may not qualify if…

• Breastfeeding (patients who discontinue breastfeeding would be considered eligible).

Where it is running

• Marin Specialty Care, Inc — Greenbrae, California, United States
• The Angeles Clinic & Research Institute — Los Angeles, California, United States
• Kaiser Permanente Los Angeles Medical Center — Los Angeles, California, United States
• Kaiser Permanente West Los Angeles — Los Angeles, California, United States
• Kaiser Permanente Moreno Valley — Moreno Valley, California, United States
• University of Colorado Health Hospital — Aurora, Colorado, United States
• UCHealth Cancer Center — Fort Collins, Colorado, United States
• Baptist MD Anderson Cancer Center — Jacksonville, Florida, United States
• Mayo Clinic in Florida — Jacksonville, Florida, United States
• Ocala Oncology, P.A. — Ocala, Florida, United States
• Florida Cancer Specialists — Orlando, Florida, United States
• Orlando Health UF Health Cancer Center — Orlando, Florida, United States
• Florida Cancer Specialists — Sarasota, Florida, United States
• Oncology-Hematology Associates of West Broward — Tamarac, Florida, United States
• Northside Hospital — Athens, Georgia, United States
• Tift Regional Health System Anita Stewart Oncology Center — Tifton, Georgia, United States
• Beacon Cancer Care — Coeur d'Alene, Idaho, United States
• Rush University Medical Center — Chicago, Illinois, United States
• Illinois Cancer Care — Peoria, Illinois, United States
• Hematology Oncology Clinic — Baton Rouge, Louisiana, United States
• Alton Ochsner Medical Center — New Orleans, Louisiana, United States
• University of Maryland, Baltimore — Baltimore, Maryland, United States
• SKCCC at Johns Hopkins — Baltimore, Maryland, United States
• Baltimore Washington Health Services — Glen Burnie, Maryland, United States
• Ironwood Cancer & Research Centers — Glendale, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.